Comparative Pharmacology
Head-to-head clinical analysis: AN DTPA versus MPI DMSA KIDNEY REAGENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AN DTPA versus MPI DMSA KIDNEY REAGENT.
AN-DTPA vs MPI DMSA KIDNEY REAGENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AN-DTPA (pentetate calcium trisodium) is a chelating agent that binds to and removes heavy metals, such as plutonium, americium, curium, and other transuranic elements, from the body. It forms stable complexes with these metals, which are then excreted via the kidneys.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
1 gram by intravenous injection or infusion daily for 5 consecutive days, starting immediately after the end of radiotherapy.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5-2 hours in patients with normal renal function. Extended significantly in renal impairment (up to 24 hours in anuria).
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Renal: >95% as unchanged drug via glomerular filtration. Biliary/fecal: <5%.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical